Patents Assigned to Wyeth LLC
  • Treatment of sleep disturbances
    Patent number: 8883849
    Abstract: The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: November 11, 2014
    Assignee: Wyeth LLC
    Inventors: Graham D. Cook, Todd S. Koch, David H. Giamalva, Justin Bianco, James J. Fort, Geraldine Doyle, Steven Cooper
  • MICRONIZED TANAPROGET, COMPOSITIONS, AND METHODS OF PREPARING THE SAME
    Publication number: 20140328925
    Abstract: The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.
    Type: Application
    Filed: June 2, 2014
    Publication date: November 6, 2014
    Applicant: Wyeth LLC
    Inventors: Arwinder Nagi, Ramarao Chatlapalli, Shamim Hasan, Mohamed Ghorab, Dhaval Gaglani
  • Stabilizing formulations
    Patent number: 8871201
    Abstract: Formulations are described that are suitable for storage of proteins, such as antibodies, over a relatively broad range of protein concentrations, pH, and buffer types. Also described are methods of storing a protein and methods of identifying a suitable formulation for storage of a specific protein. In general, a formulation contains low to no surfactant, no to relatively low salt concentrations, and requires a relatively low buffer concentration.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: October 28, 2014
    Assignee: Wyeth LLC
    Inventors: Li Li, Angela Kantor, Shannon B. MacMillan
  • Triazine compounds as PI3 kinase and mTOR inhibitors
    Patent number: 8859542
    Abstract: Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: October 14, 2014
    Assignee: Wyeth LLC
    Inventors: Aranapakam Mudumbai Venkatesan, Zecheng Chen, Christoph Martin Dehnhardt, Osvaldo Dos Santos, Efren Guillermo Delos Santos, Arie Zask, Jeroen Cunera Verheijen, Joshua Aaron Kaplan, David James Richard, Semiramis Ayral-Kaloustian, Tarek Suhayl Mansour, Ariamala Gopalsamy, Kevin Joseph Curran, Mengxiao Shi
  • Assembly of wild-type and chimeric influenza virus-like particles (VLPs)
    Patent number: 8859231
    Abstract: Influenza virus-like particles (VLPs) comprising the structural proteins HA, NA, M1 and M2 are described. VLPs are also generated containing M1 alone, as are VLPs with M1 and any one or two of HA, NA and M2. VLPs with HA from one influenza subtype and NA from a different influenza subtype are also described, as are VLPs in which a portion or all of HA or NA is replaced by a heterologous moiety not produced by influenza virus, so as to comprise chimeric VLPs.
    Type: Grant
    Filed: June 2, 2009
    Date of Patent: October 14, 2014
    Assignee: Wyeth LLC
    Inventors: Jose M. Galarza, Theresa E. Latham
  • Peripheral opioid receptor antagonists and uses thereof
    Patent number: 8853232
    Abstract: The present invention provides a compound of formula I: wherein R1, R2, R2? and X? are as defined and described herein, methods of manufacture thereof and compositions thereof, useful for example as peripheral mu opioid receptor antagonists in treatment of side effects of opioid administration.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: October 7, 2014
    Assignees: Wyeth LLC, Progenics Pharmaceuticals., Inc.
    Inventors: Alfred A. Avey, Appavu Chandrasekaren, Harold D. Doshan, Julio Perez, Yakov Rotshteyn
  • Processes for making hydrazides
    Patent number: 8853451
    Abstract: A method is disclosed for preparing hydrazides from hydrazine and an acyl chloride which comprises the steps of (a) preparing a stirred substantially uniform slurry comprising hydrazine and an inert solvent at low temperature; and (b) adding an acyl chloride continuously to said slurry. The method avoids or limits production of undesired bis-hydrazide by-products. The method is used to prepare 3-methyl-3-mercaptobutanoic acid hydrazide, a molecule used to link calicheamicin to a monoclonal antibody.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: October 7, 2014
    Assignee: Wyeth LLC
    Inventors: George Anello Chiarello, Ayman Sahli
  • Pyrimidine compounds, their use as mTOR kinase and Pl3 kinase inhibitors, and their syntheses
    Patent number: 8835429
    Abstract: The invention relates to pyrimidine compounds of the Formula I: or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: September 16, 2014
    Assignee: Wyeth LLC
    Inventors: Kevin Joseph Curran, Joshua Aaron Kaplan, David James Richard, Jeroen Cunera Verheijen, Arie Zask
  • Fast Dissolving Tablet
    Publication number: 20140249190
    Abstract: The present invention relates to processes for the preparation of tablets which dissolve rapidly in the mouth and provide an excellent mouthfeel. The tablets of the invention comprise a compound which melts at about 37° C. or lower, have a low hardness, high stability and generally comprise few insoluble disintegrants which may cause a gritty or chalky sensation in the mouth. Convenient and economically feasible processes by which the tablets of the invention may be produced are also provided.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 4, 2014
    Applicant: Wyeth LLC
    Inventors: Janos Szamosi, Kevin Scott Kinter, Vincent H. Li, Khawla Abdullah Abu-Izza
  • ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
    Publication number: 20140249171
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: July 31, 2013
    Publication date: September 4, 2014
    Applicant: Wyeth, LLC
    Inventors: Syed M. Shah, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • TRIAZINE COMPOUNDS AS PI3 KINASE AND MTOR INHIBITORS
    Publication number: 20140248239
    Abstract: Compounds of formula I wherein: R1 is and R2, R4, and R6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
    Type: Application
    Filed: April 23, 2014
    Publication date: September 4, 2014
    Applicant: WYETH LLC
    Inventors: Aranapakam Mudumbai VENKATESAN, Zecheng CHEN, Christoph Martin DEHNHARDT, Osvaldo DOS SANTOS, Efren Guillermo DELOS SANTOS, Arie ZASK, Jeroen Cunera VERHEIJEN, Joshua Aaron KAPLAN, David James RICHARD, Semiramis AYRAL-KALOUSTIAN, Tarek Suhayl MANSOUR, Ariamala GOPALSAMY, Kevin Joseph CURRAN, Mengxiao SHI
  • Peripheral opioid receptor antagonists and uses thereof
    Patent number: 8822490
    Abstract: The present invention provides a compound of formula I: wherein X?, R1, and R2 are as defined herein, and compositions thereof.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: September 2, 2014
    Assignee: Wyeth LLC
    Inventors: Nataliya Bazhina, George Joseph Donato, III, Steven R. Fabian, John Lokhnauth, Sreenivasulu Megati, Charles Melucci, Christian Ofslager, Niketa Patel, Galen Radebaugh, Syed M. Shah, Jan Szeliga, Huyi Zhang, Tianmin Zhu
  • 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole and estrogen formulations
    Patent number: 8815934
    Abstract: The present invention relates to new formulations containing one or more estrogens and 2-Phenyl-1-[4-(2-Aminoethoxy)-Benzyl]-Indole compounds which are useful as estrogenic agents, as well as pharmaceutical compositions and methods of treatment utilizing these compounds, which have the general structures below:
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: August 26, 2014
    Assignee: Wyeth LLC
    Inventors: James H Pickar, Barry S Komm
  • Pneumococcal dosing regimen
    Patent number: 8808707
    Abstract: Methods of immunizing older adult subjects against Streptococcus pneumoniae infection are provided. Provided methods comprise immunization of naïve adult subjects with a conjugated pneumococcal polysaccharide vaccine. Optionally, initial immunization may be followed by additional immunization doses comprising conjugated pneumococcal polysaccharide vaccine or unconjugated pneumococcal polysaccharide vaccine composition.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: August 19, 2014
    Assignee: Wyeth LLC
    Inventors: George Rainer Siber, Peter R. Paradiso, Jill G. Hackell, Stephen Paul Lockhart, William P. Hausdorff
  • Multivalent pneumococcal polysaccharide-protein conjugate composition
    Patent number: 8808708
    Abstract: An immunogenic composition having 13 distinct polysaccharide-protein conjugates and optionally, an aluminum-based adjuvant, is described. Each conjugate contains a capsular polysaccharide prepared from a different serotype of Streptococcus pneumoniae (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) conjugated to a carrier protein. The immunogenic composition, formulated as a vaccine, increases coverage against pneumococcal disease in infants and young children globally, and provides coverage for serotypes 6A and 19A that is not dependent on the limitations of serogroup cross-protection.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: August 19, 2014
    Assignee: Wyeth LLC
    Inventors: William P. Hausdorff, George Rainer Siber, Peter R. Paradiso
  • DRY POWDER COMPOUND FORMULATIONS AND USES THEREOF
    Publication number: 20140228389
    Abstract: The present invention provides lyophilized formulations comprising methylnaltrexone, and processes for preparation of provided formulations. Additionally provided are compositions and products containing the methylnaltrexone formulation, as well as methods for producing formulations, compositions and products. Provided formulations as well as compositions and products containing methylnaltrexone formulations are useful for preventing, treating delaying, diminishing or reducing the severity and/or incidence of side effects resulting from administration of analgesic opioids.
    Type: Application
    Filed: September 16, 2013
    Publication date: August 14, 2014
    Applicant: WYETH, LLC
    Inventors: Syed M. Shah, Christian Ofslager
  • MODIFIED AND STABILIZED GDF PROPEPTIDES AND USES THEREOF
    Publication number: 20140228289
    Abstract: Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).
    Type: Application
    Filed: September 19, 2013
    Publication date: August 14, 2014
    Applicant: WYETH LLC
    Inventors: Neil M. Wolfman, Soo Peang Khor, Kathleen N. Tomkinson
  • Method for controlling serotype 19A polysaccharide molecular weight
    Patent number: 8795689
    Abstract: The present invention provides improved methods for producing a solution containing high molecular weight isolated Streptococcus pneumoniae 19A capsular polysaccharides. In certain methods, a fermentation culture of Streptococcus pneumoniae bacterial cells that produce serotype 19A capsular polysaccharides is fermented for less than 6 hours before the bacterial cells are lysed the capsular polysaccharides are harvested. In other methods, CO2 is supplied to the fermentation culture. Supplying CO2 to the fermentation culture includes adding bicarbonate ions to the fermentation culture, adding carbonate ions to the fermentation culture, adding mixtures of bicarbonate and carbonate ions to the fermentation culture, and overlaying the fermentation culture with CO2.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: August 5, 2014
    Assignee: Wyeth LLC
    Inventor: Jean Heather Crinean
  • Cyclothiocarbamate derivatives as progesterone receptor modulators
    Patent number: 8796266
    Abstract: Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: wherein R1, R2, R3, R4, R5, and Q1 are defined herein.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: August 5, 2014
    Assignee: Wyeth LLC
    Inventors: Puwen Zhang, Andrew Fensome, Eugene A. Terefenko, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley, Jay E. Wrobel, Mark A. Collins
  • Anti-tumor activity of CCI-779 in papillary renal cell cancer
    Patent number: 8791097
    Abstract: This invention provides the method or use of CCI-779 in the treatment of papillary renal cell carcinoma.
    Type: Grant
    Filed: April 8, 2008
    Date of Patent: July 29, 2014
    Assignee: Wyeth LLC
    Inventors: Gary Dukart, James Joseph Gibbons, Jr., Anna Berkenblit, Jay Marshall Feingold